CarolAShermanMD

Oncology • Charleston, SC

Associate Professor of Medicine, Med University SC

Join to view full profile

Dr. Sherman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sherman's full profile

Already have an account?

Office
171 Ashley Ave
Charleston, SC 29425
Phone+1 843-792-1414

Education & Training

UMass Chan Medical SchoolFellowship, Hematology and Medical Oncology, 1987 - 1989
UMass Chan Medical SchoolResidency, Internal Medicine, 1984 - 1987
University of Massachusetts Medical SchoolClass of 1984

Certifications & Licensure

SC State Medical License 1997 - 2023
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer Start of enrollment: 1998 Nov 01
Completed
Phase 2
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers Start of enrollment: 2009 Nov 01
Completed
Phase 1
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

278 citations
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John Wrangle, Vamsidhar Velcheti, Manish R. Patel, Elizabeth Garrett-Mayer, Elizabeth G. Hill
The Lancet. Oncology. 2018-05-01
17 citations
Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer.
C. M. S. Rocha Lima, J. R. Eckardt, S. S. Leong, Carol A. Sherman, J. A. Perkel
Seminars in Oncology. 1999-12-14
121 citations
Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib
Justin F. Gainor, Carol A. Sherman, Kathryn Willoughby, Jennifer A. Logan, Elizabeth Kennedy
Journal of Thoracic Oncology. 2015-02-01